CN101049340A - A pharmaceutical composition for treating vitiligo and its preparation method - Google Patents
A pharmaceutical composition for treating vitiligo and its preparation method Download PDFInfo
- Publication number
- CN101049340A CN101049340A CN 200610067143 CN200610067143A CN101049340A CN 101049340 A CN101049340 A CN 101049340A CN 200610067143 CN200610067143 CN 200610067143 CN 200610067143 A CN200610067143 A CN 200610067143A CN 101049340 A CN101049340 A CN 101049340A
- Authority
- CN
- China
- Prior art keywords
- parts
- ethanol
- fructus
- treatment
- leukodermic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 206010047642 Vitiligo Diseases 0.000 title abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 108
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 34
- 238000002156 mixing Methods 0.000 claims abstract description 26
- 239000000706 filtrate Substances 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 22
- 238000010992 reflux Methods 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- -1 reflux Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 20
- 241001446509 Psoralea Species 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 16
- 241001180876 Saposhnikovia Species 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 11
- 150000002576 ketones Chemical class 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 238000005325 percolation Methods 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 6
- 235000006463 Brassica alba Nutrition 0.000 claims description 3
- 244000140786 Brassica hirta Species 0.000 claims description 3
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 3
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 30
- 239000011573 trace mineral Substances 0.000 abstract description 9
- 235000013619 trace mineral Nutrition 0.000 abstract description 9
- 230000004089 microcirculation Effects 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 7
- 102000003425 Tyrosinase Human genes 0.000 abstract description 6
- 108060008724 Tyrosinase Proteins 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 abstract description 3
- 208000017983 photosensitivity disease Diseases 0.000 abstract description 3
- 231100000434 photosensitization Toxicity 0.000 abstract description 3
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 2
- 230000019612 pigmentation Effects 0.000 abstract description 2
- 238000002791 soaking Methods 0.000 abstract description 2
- 238000010792 warming Methods 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 230000008099 melanin synthesis Effects 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 16
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 210000002752 melanocyte Anatomy 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 229940098465 tincture Drugs 0.000 description 7
- 239000006187 pill Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 206010025421 Macule Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 241000124079 Mylabris Species 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- XDROKJSWHURZGO-UHFFFAOYSA-N angelicin Chemical compound C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 244000145469 Vernonia anthelmintica Species 0.000 description 1
- 235000013018 Vernonia anthelmintica Nutrition 0.000 description 1
- 208000030668 Zinc disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicinal composition for treating leucoderma and a preparation method thereof. The preparation method comprises the steps of crushing the medicaments into coarse powder, soaking the coarse powder in ethanol, percolating, collecting percolate, adding ethanol into dregs of a decoction, carrying out reflux extraction, filtering, combining the filtrate and the percolate, adding azone, mixing uniformly, standing, filtering, adding ethanol into the filtrate to adjust the total amount of the ethanol, and mixing uniformly to obtain the traditional Chinese medicine composition. The invention has the advantages of definite curative effect, short course of treatment, less side effect, low recurrence rate, simple preparation process and low price, has the effects of warming skin, dispelling cold, dispelling wind and removing dampness, relaxing channels, activating collaterals, promoting blood circulation and removing blood stasis, can improve the microcirculation of the skin at the focus part, directly supplements trace elements, increases the photosensitization of the skin, activates the tyrosinase activity, promotes the synthesis of melanin in the skin and increases the pigmentation. Is suitable for patients with vitiligo to take orally or topically.
Description
One, technical field
The present invention relates to leukodermic drug regimen of a kind of treatment and preparation method thereof.
Two, background technology
Vitiligo is a kind of common depigmentation dermatoses, clinical manifestation be differ in size on the skin, shape differs, number is indefinite, well-defined depigmentation speckle, the traditional Chinese medical science is referred to as leucoderma, vitiligo.Though non-life threatening of vitiligo causes greatly with psychological pressure mentally to the patient, having a strong impact on work, study and social communication.According to statistics, China's vitiligo sickness rate accounts for dermopathic 0.54～1.03%; External report shows: U.S.'s vitiligo prevalence accounts for 1%, and Denmark accounts for 0.46%, and the India Surat accounts for 1.13%, and Calcutta accounts for 0.46%, and the French West Indies is reported as about 0.5～1%.Because the difficult always effectively Therapeutic Method of this sick etiology unknown, Chinese and western medicine.Doctor trained in Western medicine is treated with photochemotherapy usually, adds irradiation ultraviolet radiation behind the promptly oral 8-methoxyposoralen, continued treatment half a year to one year, just can obtain certain improvement.Chinese traditional treatment should the disease determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs a lot of methods such as internal treatment, external treatment, acupuncture and moxibustion treatment, scrape therapy, water phototherapy, the subcutaneous method of sunkening cord, but the course of treatment is long, also take continued treatment half a year to one year, and curative effect is limited, cure rate is low, generally is no more than 25%.The external therapy of Chinese herb vitiligo has certain curative effect, and side effect is less relatively.External treatment commonly used in general document record has following several: (1) psoralea tincture (Nanjing " hospital preparation standard " 1989) Fructus Psoraleae 300g, ethanol (75%) is an amount of.Get Fructus Psoraleae and be ground into coarse powder, add an amount of 75% ethanol lixiviate, be made into 1000ml, stir evenly, promptly.External takes a morsel and is coated with the affected part, is coated with back sun exposure 10 minutes, to heighten the effect of a treatment every day 1～2 time.(2) white macula tincture (Nanjing " hospital preparation standard " 1989) Fructus Psoraleae 60g, Semen Cuscutae 60g, Fructus Gardeniae 60g.More than 3 the flavor be ground into fine powder, with an amount of lixiviate of 70% ethanol.Get leachate 1000ml promptly.Affected part of exterior coating, every day 2 times.Behind the medicine, the affected part was shone 20 minutes under daylight.(3) tincture (" Shandong Province's drug standard " 1986) the Fructus Psoraleae 375g that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., Semen Cuscutae 563g, Nidus Vespae 281g, Mylabris (stir-fry) 0.3g.More than 4 the flavor, with 75% ethanol lixiviate, the collection extracting solution.(4) diffusing (" Jilin Province's hospital preparation standard ") Fructus Psoraleae 600g of vitiligo, Realgar 250g, above 3 flavors of Lithargyrum 250go are ground into fine powder.Cross 140 mesh sieves, mixing, promptly.The coating affected part is transferred in external, vinegar.Some oral and external used medicines in patent documentation, have also been announced, it as application number 95113704.2 the leukodermic compound Vernonia anthelmintica tablet of treatment, it comprises with Chinese medicine Caulis Vernoniae andersonii, Fructus Lycii, Fructus Psoraleae, Radix Polygoni Multiflori, Herba Ecliptae, Fructus Tribuli, Radix Rehmanniae, Radix Salviae Miltiorrhizae, Radix Glycyrrhizae, trace element copper sulfate is raw material, and also comprising with magnesium stearate, 10% starch gelatin slurry is the Chinese medicinal tablet that adjuvant is made.Usage: each 5 of adult's consumption, three times on the one, 30 days is a course of treatment.Application number is 200410075351.5 the leukodermic Chinese patent medicine of a kind of treatment, and it is standby to it is characterized in that choosing Caulis Vernoniae andersonii, the Radix Astragali, Semen Sesami Nigrum, Fructus Fici, Radix Salviae Miltiorrhizae, the Radix Angelicae Dahuricae, Fructus Psoraleae, Flos Carthami eight flavor pulverize at low temperature to 120 mesh sieve fine powders; With Cortex Dictamni, Fructus Tribuli, the Radix Polygoni Multiflori, Herba Ecliptae, Radix Arnebiae (Radix Lithospermi), the Poria Six-element is cataclasm, water decocts secondary, 3 hours for the first time, 2 hours for the second time, filter, discard residue, collecting decoction, filtrate is condensed into thick paste; Mix with standby fine powder, drying is ground into impalpable powder, and mixing carried out ripening, sterilization treatment 20～30 minutes under 100～110 ℃ of temperature, make powder; With the powder water pill, freeze-day with constant temperature is used the Pulvis Talci coating, and polishing makes pill; Powder is filled with the Capsules shell, and grain is picked up in polishing, makes capsule.Be oral formulations.Application number is a kind of treatment vitiligo medicine of 93114696.8, and it contains Caulis Vernoniae andersonii, Fructus Psoraleae, Fructus Mume, and dash by the material group that Flos Caryophylli, Semen Sinapis Albae, Semen Sesami Nigrum, azone are formed one or more.Application number is 01114723.7 a kind of Kebai Tincture, its preparation method and application, by Mylabris 30～70 grams, and Fructus Psoraleae 100～300 grams, Pericarpium Citri Reticulatae 50～200 grams, 1000 milliliters of compositions of 75%～95% ethanol.Application number is 03118540.1 the leukodermic compound recipe Fructus Psoraleae of treatment preparation, it be by the alcohol-pickled liquid of mending bone ester, Semen Cuscutae, the Fructus Kochiae, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Flos Carthami, Radix Sophorae Flavescentis add azone, dexamethasone or and Le-Fu-Ye bacteriostatic formulated.Application number is 200410044147.7 treatment vitiligo Chinese herbal medicine liniment, and it comprises Fructus Atriplicis Sibiricae, Flos Carthami, Fructus Psoraleae, melanin.Fructus Atriplicis Sibiricae, Flos Carthami, Fructus Psoraleae, melanic ratio are 1: 1: 1: 5; Preparation method is that waste is got leachate after getting Fructus Atriplicis Sibiricae 1000g, Flos Carthami 1000g, Fructus Psoraleae 1000g and soaking 3 days with 75% medical ethanol respectively, Fructus Psoraleae mixed with Flos Carthami, Fructus Atriplicis Sibiricae, the melanin mix homogeneously through being concentrated into 1000ml and 5000g.Above preparation or patent weak point are: curative effect is low, the course of treatment is long, and the external preparation side effect that part contains toxic medicament such as Mylabris, Lithargyrum is bigger.The present invention be with form through clinical screening for many years through proved recipe, characteristics such as have determined curative effect, short treating period, few side effects, relapse rate is low, preparing process is simple, price is low.
Three, summary of the invention
The object of the present invention is to provide a kind of determined curative effect, short treating period, few side effects, relapse rate is low, preparing process is simple, price is low leukodermic drug regimen of treatment and preparation method thereof, be applicable to patients with vitiligo.
Technical scheme of the present invention: the leukodermic drug regimen of a kind of treatment is to be that main medicine is made by Caulis Vernoniae andersonii, Fructus Psoraleae, Radix Angelicae Sinensis, Radix Saposhnikoviae, Fructus Cnidii, it is characterized in that the medicament that mainly is prepared from by following raw material composition and weight proportion: 10～60 parts of Caulis Vernoniae andersoniis, 10～60 parts of Fructus Psoraleaes, 5～50 parts of Radix Angelicae Sinensis, 5～50 parts of Radix Saposhnikoviaes, 5～50 parts of Fructus Cnidiis; Preferred weight ratio range of the present invention is: 20～50 parts of Caulis Vernoniae andersoniis, 20～50 parts of Fructus Psoraleaes, 10～40 parts of Radix Angelicae Sinensis, 10～40 parts of Radix Saposhnikoviaes, 10～40 parts of Fructus Cnidiis; Optimum weight ratio range of the present invention is: 30 parts of Caulis Vernoniae andersoniis, 30 parts of Fructus Psoraleaes, 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Saposhnikoviaes, 20 parts of Fructus Cnidiis.
This prescription also can add 10～40 parts of Rhizoma Et Radix Notopterygiis and or 10～40 parts of increases of Radix Angelicae Pubescentis dispeiling pathogenic wind and removing dampness effect.
This prescription also can add 10～40 parts of Flos Caryophyllis and or 10～40 parts of increases of Fructus Foeniculi dispelling cold by warming the meridian effect.
This prescription also can add 10～40 parts on Flos Carthami, and Semen Persicae increases function of promoting blood circulation to disperse blood clots for 10～40 parts.
This prescription also can add 10～40 parts of Cortex Dictamni, and Semen Sinapis Albae increases the eliminating dampness and dredging channels effect for 10～40 parts.
This prescription also can add 10～40 parts of Radix Polygoni Multiflori, and Fructus Mume increases the effect of the kidney invigorating skin moistening for 10～40 parts.
A kind of preparation method for the treatment of leukodermic drug regimen is characterized in that it is by above-mentioned raw materials combination and weight proportion, is ground into coarse powder, carry out percolation after 1～3 day with 50～70% soak with ethanol, collect percolate, medicinal residues add 50～70% ethanol, reflux, extract, 2～6 hours filters, and filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
As above-mentioned a kind of preparation method for the treatment of leukodermic drug regimen, it is characterized in that the dosage form by above-mentioned raw materials combination and weight proportion preparation is any dosage form that adopts pharmaceutically acceptable carrier or excipient to make, as tincture, granule, tablet, capsule, soft capsule, drop pill, pill etc.
The invention has the advantages that the prescription uniqueness, determined curative effect, short treating period, few side effects, relapse rate is low, preparing process is simple, price is low, has warm skin cold expelling, dispeiling pathogenic wind and removing dampness, soothing the channels and quicking the network vessels, and the effect of blood circulation promoting and blood stasis dispelling is applicable to patients with vitiligo external or for oral administration.The present invention it be with form through clinical screening for many years through proved recipe, its characteristics are to improve the microcirculation of lesions position skin, directly trace element supplement, increase the photosensitization of skin, activity of tyrosinase promotes melanic synthesizing in the skin, increases pigmentation.Modern pharmacological research shows that effect of the present invention mainly shows following several respects: (1) activity of tyrosinase: tryrosinase is the biosynthetic key enzyme of skin melanocyte, its activity is relevant with the melanocyte synthetic quantity, increases the growing amount that its vigor can increase melanocyte.Caulis Vernoniae andersonii, Fructus Psoraleae, Fructus Cnidii, Cortex Dictamni, Fructus Mume, Radix Saposhnikoviae, Radix Angelicae Sinensis all have activation to tryrosinase in this prescription of modern pharmacological research, and tyrosinase activity and melanocyte growing amount all are the dose dependent activation.This medicine up to 73.18%, is 2.7 times of psoralea tincture to the activity ratio of tryrosinase after testing.(2) improve the skin photosensitization: contain the ultraviolet photosensitive material of absorption psoralen and isopsoralen one by one in this prescription in the medicines such as Fructus Psoraleae, Radix Polygoni Multiflori, Fructus Cnidii, Radix Saposhnikoviae, Cortex Dictamni, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, can improve skin to ultraviolet sensitivity, suppress the sulfydryl in the epidermis, increase tyrosinase activity and stimulate melanocyte to make its restore funcitons, the skin melanin regeneration.(3) direct local trace element supplement: medicine such as this prescription Caulis Vernoniae andersonii is rich in the human body various trace elements after testing, and is as copper, zinc, ferrum, manganese, cobalt, selenium etc., wherein the closest with the relation of copper, zinc and primary disease.Copper ion is the activator of tryrosinase, contains the zinc of high concentration in the melanin granule, lacks trace element such as copper, zinc, ferrum, manganese and can make tyrosinase activity reduce the melanocyte biosynthesis block.Patients with vitiligo is carried out trace elements determination can be found, most patient's bodies are interior and have no lack of trace element, are to lack in the local white macula.This product can direct local trace element supplement, thereby can effectively activate tryrosinase, promotes melanocyte synthetic.(4) improve the local microcirculation obstacle: microcirculation and vitiligo have close association, microcirculation mensuration is carried out at the white macula position also can be found, on the skin of the same area, the blood capillary number of suffering from the vitiligo position will lack more than the normal skin position, show that the white macula happening part exists microcirculation disturbance, make nutritional labeling can not deliver to each position of skin, melanocyte can not normally be nourished and influenced its growth promoter, metabolism.Year in and year out, the melanocyte dyspoiesis, melanin takes off mistake, thereby the local skin decolouring is bleached, and the vitiligo focus occurs.This prescription has warm skin cold expelling, dispeiling pathogenic wind and removing dampness, soothing the channels and quicking the network vessels, and the effect of blood circulation promoting and blood stasis dispelling can be improved the microcirculation of lesions position skin, corrects qi depression to blood stasis, blockage of meridian and failure of skin and muscle to be nourished state, thereby promotes melanocyte synthetic.Modern study shows that medicines energy blood vessel dilating such as Fructus Psoraleae, Cortex Dictamni, Caulis Vernoniae andersonii, Flos Carthami, Semen Persicae improve local organization nutrition in this prescription, and skin pigment is increased.
Four, the specific embodiment
With specific embodiment the present invention is elaborated below:
Embodiment 1:
Take by weighing raw material according to following proportioning: 15 parts of Caulis Vernoniae andersoniis, 15 parts of Fructus Psoraleaes, 10 parts of Radix Angelicae Sinensis, 10 parts of Radix Saposhnikoviaes, 10 parts of Fructus Cnidiis.
Preparation method: above-mentioned raw materials is ground into coarse powder, carries out percolation after 1～3 day, collect percolate with 50～70% soak with ethanol, medicinal residues add 50～70% ethanol, and reflux, extract, 2～6 hours filters, filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
Wherein, finished dosage forms is any dosage form that adopts pharmaceutically acceptable carrier or excipient to make, as tincture, granule, tablet, capsule, soft capsule, drop pill, pill etc.Down together.
Embodiment 2:
Take by weighing raw material according to following proportioning: 55 parts of Caulis Vernoniae andersoniis, 55 parts of Fructus Psoraleaes, 45 parts of Radix Angelicae Sinensis, 45 parts of Radix Saposhnikoviaes, 45 parts of Fructus Cnidiis.
Preparation method: above-mentioned raw materials is ground into coarse powder, carries out percolation after 1～3 day, collect percolate with 50～70% soak with ethanol, medicinal residues add 50～70% ethanol, and reflux, extract, 2～6 hours filters, filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
Embodiment 3:
Take by weighing raw material according to following proportioning: 30 parts of Caulis Vernoniae andersoniis, 30 parts of Fructus Psoraleaes, 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Saposhnikoviaes, 20 parts of Fructus Cnidiis.
Preparation method: above-mentioned raw materials is ground into coarse powder, carries out percolation after 1～3 day, collect percolate with 50～70% soak with ethanol, medicinal residues add 50～70% ethanol, and reflux, extract, 2～6 hours filters, filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
Embodiment 4:
Take by weighing raw material according to following proportioning: 30 parts of Caulis Vernoniae andersoniis, 30 parts of Fructus Psoraleaes, 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Saposhnikoviaes, 20 parts of Fructus Cnidiis, 15 parts of Rhizoma Et Radix Notopterygiis, 15 parts of Radix Angelicae Pubescentiss.
Preparation method: above-mentioned raw materials is ground into coarse powder, carries out percolation after 1～3 day, collect percolate with 50～70% soak with ethanol, medicinal residues add 50～70% ethanol, and reflux, extract, 2～6 hours filters, filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
Embodiment 5:
Take by weighing raw material according to following proportioning: 30 parts of Caulis Vernoniae andersoniis, 30 parts of Fructus Psoraleaes, 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Saposhnikoviaes, 20 parts of Fructus Cnidiis, 15 parts of Flos Caryophyllis, 15 parts of Fructus Foeniculi.
Preparation method: above-mentioned raw materials is ground into coarse powder, carries out percolation after 1～3 day, collect percolate with 50～70% soak with ethanol, medicinal residues add 50～70% ethanol, and reflux, extract, 2～6 hours filters, filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
Embodiment 6:
Take by weighing raw material according to following proportioning: 30 parts of Caulis Vernoniae andersoniis, 30 parts of Fructus Psoraleaes, 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Saposhnikoviaes, 20 parts of Fructus Cnidiis, 15 parts on Flos Carthami, 15 parts in Semen Persicae.
Preparation method: above-mentioned raw materials is ground into coarse powder, carries out percolation after 1～3 day, collect percolate with 50～70% soak with ethanol, medicinal residues add 50～70% ethanol, and reflux, extract, 2～6 hours filters, filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
Embodiment 7:
Take by weighing raw material according to following proportioning: 30 parts of Caulis Vernoniae andersoniis, 30 parts of Fructus Psoraleaes, 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Saposhnikoviaes, 20 parts of Fructus Cnidiis, 20 parts of Cortex Dictamni, 10 parts of Semen Sinapis Albaes.
Preparation method: above-mentioned raw materials is ground into coarse powder, carries out percolation after 1～3 day, collect percolate with 50～70% soak with ethanol, medicinal residues add 50～70% ethanol, and reflux, extract, 2～6 hours filters, filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
Embodiment 8:
Take by weighing raw material according to following proportioning: 30 parts of Caulis Vernoniae andersoniis, 30 parts of Fructus Psoraleaes, 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Saposhnikoviaes, 20 parts of Fructus Cnidiis, 10 parts of Radix Polygoni Multiflori, 15 parts of Fructus Mumes.
Preparation method: above-mentioned raw materials is ground into coarse powder, carries out percolation after 1～3 day, collect percolate with 50～70% soak with ethanol, medicinal residues add 50～70% ethanol, and reflux, extract, 2～6 hours filters, filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
Embodiment 9:
Take by weighing raw material according to following proportioning: 30 parts of Caulis Vernoniae andersoniis, 30 parts of Fructus Psoraleaes, 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Saposhnikoviaes, 20 parts of Fructus Cnidiis, 15 parts of Rhizoma Et Radix Notopterygiis, 15 parts of Radix Angelicae Pubescentiss, 15 parts on Flos Carthami, 15 parts in Semen Persicae, 10 parts of Radix Polygoni Multiflori, 15 parts of Fructus Mumes, 15 parts of Flos Caryophyllis, 15 parts of Fructus Foeniculi, 20 parts of Cortex Dictamni, 10 parts of Semen Sinapis Albaes.
Preparation method: above-mentioned raw materials is ground into coarse powder, carries out percolation after 1～3 day, collect percolate with 50～70% soak with ethanol, medicinal residues add 50～70% ethanol, and reflux, extract, 2～6 hours filters, filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
Claims (10)
1, the leukodermic drug regimen of a kind of treatment is characterized in that the medicament that mainly is prepared from by following primary raw material and weight proportion: 10～60 parts of Caulis Vernoniae andersoniis, 10～60 parts of Fructus Psoraleaes, 5～50 parts of Radix Angelicae Sinensis, 5～50 parts of Radix Saposhnikoviaes, 5～50 parts of Fructus Cnidiis.
2, as the leukodermic drug regimen of claims 1 described a kind of treatment, the weight proportion of its raw material is: 20～50 parts of Caulis Vernoniae andersoniis, 20～60 parts of Fructus Psoraleaes, 10～40 parts of Radix Angelicae Sinensis, 10～40 parts of Radix Saposhnikoviaes, 10～40 parts of Fructus Cnidiis.
3, as the leukodermic drug regimen of claims 1,2 described a kind of treatments, the weight proportion of its raw material is: 30 parts of Caulis Vernoniae andersoniis, 30 parts of Fructus Psoraleaes, 15 parts of Radix Angelicae Sinensis, 15 parts of Radix Saposhnikoviaes, 20 parts of Fructus Cnidiis.
4,, it is characterized in that its prescription also comprises and add 10～40 parts of Rhizoma Et Radix Notopterygiis and or 10～40 parts of Radix Angelicae Pubescentiss as the leukodermic drug regimen of claims 1～3 described a kind of treatment.
5,, it is characterized in that its prescription also comprises and add 10～40 parts of Flos Caryophyllis and or 10～40 parts of Fructus Foeniculi as the leukodermic drug regimen of claims 1～4 described a kind of treatment.
6,, it is characterized in that its prescription also comprises 10～40 parts on adding Flos Carthami, 10～40 parts in Semen Persicae as the leukodermic drug regimen of claims 1～5 described a kind of treatment.
7,, it is characterized in that its prescription also comprises 10～40 parts of adding Cortex Dictamni, 10～40 parts of Semen Sinapis Albaes as the leukodermic drug regimen of claims 1～5 described a kind of treatment.
8,, it is characterized in that its prescription also comprises 10～40 parts of adding Radix Polygoni Multiflori, 10～40 parts of Fructus Mumes as the leukodermic drug regimen of claims 1～5 described a kind of treatment.
9, as claims 1～8 described a kind of preparation method for the treatment of leukodermic drug regimen, it is characterized in that it is by above-mentioned raw materials and combination matching, is ground into coarse powder, carry out percolation after 1～3 day with 50～70% soak with ethanol, collect percolate, medicinal residues add 50～70% ethanol, reflux, extract, 2～6 hours filters, and filtrate and above-mentioned percolate merge, add the fine and soft ketone of 2% nitrogen, mixing left standstill 24 hours, filter, filtrate adds 60% ethanol and adjusts the ethanol total amount, mixing, promptly.
10,, it is characterized in that by above-mentioned raw materials and combination matching dosage form be any dosage form that adopts pharmaceutically acceptable carrier or excipient to make as claims 9 described a kind of preparation methoies for the treatment of leukodermic drug regimen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610067143 CN101049340A (en) | 2006-04-05 | 2006-04-05 | A pharmaceutical composition for treating vitiligo and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610067143 CN101049340A (en) | 2006-04-05 | 2006-04-05 | A pharmaceutical composition for treating vitiligo and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101049340A true CN101049340A (en) | 2007-10-10 |
Family
ID=38781076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610067143 Pending CN101049340A (en) | 2006-04-05 | 2006-04-05 | A pharmaceutical composition for treating vitiligo and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101049340A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101306141B (en) * | 2008-06-06 | 2011-10-26 | 叶志军 | Decoction for treating qi-blood disharmony type vitiligo |
| CN102228544A (en) * | 2011-07-11 | 2011-11-02 | 山东新宝医药有限公司 | Traditional Chinese medicine composition for treating leucoderma and preparation method thereof |
| CN103230584A (en) * | 2013-03-26 | 2013-08-07 | 成进学 | Cobalt, copper, selenium, traditional Chinese medicine element, and vitamin leucoderma-treating external medicinal liquor |
| CN103461611A (en) * | 2013-10-09 | 2013-12-25 | 北京绿源求证科技发展有限责任公司 | Food health tea infusion dissolved medicine for improving vitiligo |
| CN103933336A (en) * | 2014-04-15 | 2014-07-23 | 郎溪县志瑞企业信息服务有限公司 | Traditional Chinese medicine combination for treating leucoderma |
| CN111317810A (en) * | 2020-04-21 | 2020-06-23 | 佰氏健康(广州)大健康科技有限公司 | Traditional Chinese medicine for treating leucoderma |
| CN114796311A (en) * | 2021-01-27 | 2022-07-29 | 保定华仁白癜风医院 | Pill of vernonia amygdalina for eliminating leukosis |
-
2006
- 2006-04-05 CN CN 200610067143 patent/CN101049340A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101306141B (en) * | 2008-06-06 | 2011-10-26 | 叶志军 | Decoction for treating qi-blood disharmony type vitiligo |
| CN102228544A (en) * | 2011-07-11 | 2011-11-02 | 山东新宝医药有限公司 | Traditional Chinese medicine composition for treating leucoderma and preparation method thereof |
| CN102228544B (en) * | 2011-07-11 | 2012-07-04 | 山东新宝医药有限公司 | Traditional Chinese medicine composition for treating leucoderma and preparation method thereof |
| CN103230584A (en) * | 2013-03-26 | 2013-08-07 | 成进学 | Cobalt, copper, selenium, traditional Chinese medicine element, and vitamin leucoderma-treating external medicinal liquor |
| CN103461611A (en) * | 2013-10-09 | 2013-12-25 | 北京绿源求证科技发展有限责任公司 | Food health tea infusion dissolved medicine for improving vitiligo |
| CN103933336A (en) * | 2014-04-15 | 2014-07-23 | 郎溪县志瑞企业信息服务有限公司 | Traditional Chinese medicine combination for treating leucoderma |
| CN111317810A (en) * | 2020-04-21 | 2020-06-23 | 佰氏健康(广州)大健康科技有限公司 | Traditional Chinese medicine for treating leucoderma |
| CN114796311A (en) * | 2021-01-27 | 2022-07-29 | 保定华仁白癜风医院 | Pill of vernonia amygdalina for eliminating leukosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1840128A (en) | Medicine for treating cardiovascular disease | |
| CN1857690A (en) | Gynecopathy treating preparation and its preparing process | |
| CN101049340A (en) | A pharmaceutical composition for treating vitiligo and its preparation method | |
| CN101485825A (en) | Chinese medicine capsule for treating diabetes | |
| CN1486740A (en) | Chinese medicine composition for treating cancer | |
| CN1060657C (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1762454A (en) | Chinese traditional medicinal composition for treating psoriasis | |
| CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
| CN1351872A (en) | Chinese herbal medicine for curing comedo and acne | |
| CN104225507A (en) | Chinese medicine for treating limb paralysis and pain caused by cerebral hemorrhage | |
| CN1192922A (en) | Preparatory Chinese-medicine for treatment of hepatitis and hepatoascites | |
| CN100398143C (en) | Medicament for treating vitiligo | |
| CN1111045C (en) | Chewing medicine for treating facial paralysis and its preparing process | |
| CN100402077C (en) | Medicinal composition for treating hyperosteogency | |
| CN1814163A (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN112755137B (en) | Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof | |
| CN116459303B (en) | Chinese medicinal preparation for treating vitiligo and preparation method thereof | |
| CN102430026A (en) | Medicine for removing macula | |
| CN102743531B (en) | Drug for treating cervical or lumbar diseases and preparation method thereof | |
| CN102370838B (en) | Kidney-invigorating and tendon-reinforcing double-phase capsule | |
| CN1813876A (en) | Xian Pengliaofu oral preparation-a Chinese medicine for treating bone disease | |
| CN101062233A (en) | Powdered medicine for coaptation and its preparing process | |
| CN1895463A (en) | Chinese-medicinal preparation for treating prostatic disease | |
| CN104306585A (en) | Traditional Chinese medicine combination for curing prostatitis, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20071010 |